Key result
Genetic testing in cardiomyopathy guides risk stratification, targeted therapy, surveillance, and cascade family screening.
Integrating genetic testing with phenotypic evaluation in cardiomyopathy patients enables targeted clinical decision-making, including arrhythmic risk stratification, selection of disease-specific therapies, timely transplant evaluation, and cascade family screening.
Answers are grounded in this paper and cite their sources.
Supports genetic testing integration in cardiomyopathy care; leaves open need for prospective outcome validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Udovičić et al. (2026) conducted a review in Cardiomyopathy. Genetic testing and molecular diagnostics was evaluated. Genetic testing in cardiomyopathy informs arrhythmic risk assessment, specific therapy selection, heart failure surveillance, and targeted cascade family screening.
Synapse has enriched 10 related papers. Consider them for comparative context: